Citadel Advisors’s Ventyx Biosciences VTYX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-1,367,000
| Closed | -$12.3M | – | 14355 |
|
|
2025
Q4 | $12.3M | Buy |
1,367,000
+1,349,900
| +7,894% | +$10.1M | ﹤0.01% | 2973 |
|
|
2025
Q3 | $53.2K | Sell |
17,100
-2,000
| -10% | -$5.3K | ﹤0.01% | 12165 |
|
|
2025
Q2 | $40.9K | Sell |
19,100
-2,300
| -11% | -$3.71K | ﹤0.01% | 11869 |
|
|
2025
Q1 | $24.6K | Sell |
21,400
-37,900
| -64% | -$65.1K | ﹤0.01% | 12990 |
|
|
2024
Q4 | $130K | Buy |
59,300
+21,400
| +56% | +$48.5K | ﹤0.01% | 11089 |
|
|
2024
Q3 | $82.6K | Sell |
37,900
-28,100
| -43% | -$64.6K | ﹤0.01% | 11374 |
|
|
2024
Q2 | $152K | Buy |
66,000
+19,200
| +41% | +$79.8K | ﹤0.01% | 10327 |
|
|
2024
Q1 | $257K | Sell |
46,800
-39,900
| -46% | -$182K | ﹤0.01% | 9798 |
|
|
2023
Q4 | $214K | Buy |
86,700
+76,000
| +710% | +$722K | ﹤0.01% | 9823 |
|
|
2023
Q3 | $372K | Sell |
10,700
-500
| -4% | -$17.3K | ﹤0.01% | 8708 |
|
|
2023
Q2 | $367K | Buy |
11,200
+5,600
| +100% | +$193K | ﹤0.01% | 8592 |
|
|
2023
Q1 | $188K | Buy |
5,600
+4,100
| +273% | +$159K | ﹤0.01% | 10293 |
|
|
2022
Q4 | $49.2K | Sell |
1,500
-21,600
| -94% | -$640K | ﹤0.01% | 12164 |
|
|
2022
Q3 | $806K | Buy |
+23,100
| New | +$511K | ﹤0.01% | 7460 |
|
Other funds holding VTYX
Citadel Advisors's VTYX Position: Q1 2026 in Review
Citadel Advisors sold out of Ventyx Biosciences (VTYX) in Q1 2026, closing a stake of 1,563,611 shares — an estimated $14.1M sold.
Citadel Advisors first reported a position in VTYX in Q4 2021 and held it in 17 quarters. The position peaked at $124M in Q4 2022. 1 fund tracked by Wall St. Rank holds VTYX as of Q1 2026.
- Citadel Advisors reported no remaining Ventyx Biosciences position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 1,563,611 Ventyx Biosciences shares in Q1 2026, an estimated $14.1M.
- Citadel Advisors first reported a position in Ventyx Biosciences in Q4 2021 and held it in 17 quarters.
- Citadel Advisors's Ventyx Biosciences position peaked at $124M in Q4 2022.
- 1 fund tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.